The interleukin-8 receptor: a potential target for antipsoriatic therapy?
Interleukin-8 is assumed to play a central role in the pathogenesis of psoriasis. Since an increased expression of the interleukin-8 receptor has been observed both in polymorphonuclear leukocytes and in affected psoriatic epidermis, we were interested in whether the interleukin-8 receptor could be a molecular target of antipsoriatic compounds. Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected. In addition, the interleukin-8-induced human leukocyte antigen-DR (HLA-DR) expression of keratinocytes was nearly completely blocked by treatment of the cells with these substances. The inhibition of the keratinocyte interleukin-8 receptor and its function by antipsoriatic drugs may contribute to their therapeutic action.
Kemény
L
L
Department of Dermatology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Kenderessy
A S
AS
Olasz
E
E
Michel
G
G
Ruzicka
T
T
Farkas
B
B
Dobozy
A
A
D000875:Anthralin / Q000494:pharmacology; D002117:Calcitriol / Q000031:analogs & derivatives / Q000494:pharmacology; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy*; D018123:Receptors, Interleukin / Q000187:drug effects*; D023062:Receptors, Interleukin-8A; D011994:Recombinant Proteins / Q000494:pharmacology
D006684:HLA-DR Antigens; D016209:Interleukin-8; D018123:Receptors, Interleukin; D023062:Receptors, Interleukin-8A; D011994:Recombinant Proteins; C055085:calcipotriene; D016572:Cyclosporine; D002117:Calcitriol; D000875:Anthralin